Suppr超能文献

新冠后帕金森综合征及与新冠疫苗相关的运动障碍的发病率和特征

Incidence and characteristics of post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines.

作者信息

Dulski Jarosław, Sławek Jarosław

机构信息

Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.

Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Poland.

出版信息

Neurol Neurochir Pol. 2023;57(1):53-62. doi: 10.5603/PJNNS.a2023.0011. Epub 2023 Feb 17.

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is an infectious disease mainly affecting the respiratory system; however, a significant prevalence of neurological symptoms has been noted.

OBJECTIVES

To investigate the incidence and characteristics of post-COVID-19 parkinsonism and to study dyskinesia related to COVID-19 vaccines.

MATERIAL AND METHODS

The MEDLINE, PubMed, Scopus, and Web of Science databases were searched for all manuscripts relevant to post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines. Subsequently, we extracted and analysed data from the manuscripts in a structured manner.

RESULTS

We found 24 patients with post-COVID-19 parkinsonism, with a mean onset age of 58 years after a mean of 30 days from the COVID-19 onset. Akinetic-rigid (n = 11) and mixed (n = 6) subtypes were the most common. Asymmetry was present in 13/15 patients. Brain MRI was unremarkable in 11/19, whereas dopaminergic system imaging was abnormal in 8/8 patients. Responsiveness to dopaminergic treatment was observed in 12/15 patients. Four patients improved after immunomodulatory therapy. Comorbidities were present in 9/24, encephalopathy symptoms in 11/24, and loss of smell in 9/13 patients. Most patients (n = 14) suffered serious COVID-19- related complications and three were treated with haloperidol. Parkinsonism improved (n = 5) or resolved (n = 4) during the follow-up. Five patients, with a mean age of 52, developed dyskinesia at a mean of 25 hours after receiving the COVID-19 mRNA vaccines. One patient had a history of neuropsychiatric symptoms and developed functional dyskinesia of the tongue. Four patients had a previous history of Parkinson's Disease (PD) with a mean duration of 10 years and developed dyskinesia and dystonia, which resolved (n = 2) or improved (n = 2) during the follow-up.

CONCLUSIONS

Post-COVID-19 parkinsonism is a very rare complication, and it is likely that this is an umbrella syndrome that includes many different etiologies. Dyskinesia due to COVID-19 vaccines is exceedingly rare and probably has the same pathophysiological basis as in other conditions with exacerbation of PD symptoms.

摘要

背景

2019冠状病毒病(COVID-19)是一种主要影响呼吸系统的传染病;然而,已注意到神经系统症状的显著流行。

目的

调查COVID-19后帕金森综合征的发病率和特征,并研究与COVID-19疫苗相关的运动障碍。

材料与方法

在MEDLINE、PubMed、Scopus和Web of Science数据库中搜索所有与COVID-19后帕金森综合征和与COVID-19疫苗相关的运动障碍相关的手稿。随后,我们以结构化方式提取并分析了手稿中的数据。

结果

我们发现24例COVID-19后帕金森综合征患者,平均发病年龄为58岁,自COVID-19发病平均30天后起病。运动迟缓-强直型(n = 11)和混合型(n = 6)亚型最为常见。13/15例患者存在不对称性。11/19例患者的脑部MRI无明显异常,而8/8例患者的多巴胺能系统成像异常。12/15例患者对多巴胺能治疗有反应。4例患者在免疫调节治疗后病情改善。9/24例患者存在合并症,11/24例患者有脑病症状,9/13例患者有嗅觉丧失。大多数患者(n = 14)患有严重的COVID-19相关并发症,3例患者接受了氟哌啶醇治疗。帕金森综合征在随访期间有所改善(n = 5)或缓解(n = 4)。5例平均年龄为52岁的患者在接种COVID-19 mRNA疫苗后平均25小时出现运动障碍。1例患者有神经精神症状病史,出现舌部功能性运动障碍。4例患者既往有帕金森病(PD)病史,平均病程10年,出现运动障碍和肌张力障碍,随访期间缓解(n = 2)或改善(n = 2)。

结论

COVID-19后帕金森综合征是一种非常罕见的并发症,很可能是一种包括许多不同病因的综合征。COVID-19疫苗引起的运动障碍极为罕见,其病理生理基础可能与其他使PD症状加重的情况相同。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验